United States Multiomics Market By Product & Service (Instruments, Consumables, Software, Services), By Platform (Genomics, Transcriptomics, Proteomics, Metabolomics, Integrated Omics Platforms), By Region and Competition, Forecast & Opportunities, 2020-2030F
Market Overview
United States Multiomics Market was valued at USD 1.03 Billion in 2024 and is expected to reach USD 1.39 Billion by 2030 with a CAGR of 5.28%. Multiomics integrates data from multiple molecular layers to offer a more holistic view of health, disease, and drug response, making it a powerful tool in precision medicine, drug discovery, and clinical diagnostics. In the U.S., this market is expanding due to strong investment in life sciences research, increasing adoption of personalized healthcare, and the availability of advanced technological platforms.
Academic institutions, biotechnology firms, and pharmaceutical companies are leveraging multiomics to uncover complex disease mechanisms, identify novel biomarkers, and develop more targeted therapies. Despite its potential, the U.S. multiomics market faces challenges, particularly in terms of data integration, standardization, and interpretation. Managing large, complex datasets across different omics platforms requires robust bioinformatics capabilities and advanced computational infrastructure. There is also a growing need for skilled professionals who can bridge the gap between molecular biology and data science.
Key Market Drivers
Growth in Healthcare Industry
The growth of the healthcare industry in the United States is a major driver of the expanding multiomics market. In 2023, U.S. healthcare expenditures increased by 7.5%, reaching a total of USD 4.9 trillion, equivalent to approximately USD 14,570 per capita. This spending represented 17.6% of the country’s Gross Domestic Product (GDP). As the sector shifts toward precision medicine and data-driven care, the demand for comprehensive, multi-layered biological analysis has surged. Multiomics, an integrated approach that combines genomics, proteomics, transcriptomics, metabolomics, and other “omics” technologies is increasingly seen as essential to understanding complex diseases and tailoring more effective treatments.
One of the most significant factors fueling this demand is the healthcare industry’s emphasis on personalized medicine. For instance, USP, headquartered in Maryland, is committed to ensuring a reliable and consistent supply of safe, high-quality medicines. Leveraging scientific expertise and capacity-building solutions, USP develops standards, practical tools, and resources that empower healthcare professionals to deliver optimal personalized care across all healthcare environments. With a growing focus on treatments that are customized to an individual’s unique biological profile, healthcare providers and researchers are turning to multiomics to uncover deeper molecular insights.
Key Market Challenges
Asymptomatic Nature of HSV Infections
The asymptomatic nature of HSV infections presents a unique challenge for the United States multiomics market, particularly in efforts to develop diagnostic tools and personalized treatment strategies. Since a significant proportion of individuals infected with Herpes Simplex Virus do not exhibit noticeable symptoms, detecting and studying the virus becomes inherently difficult. This silent transmission complicates sample collection and patient identification, which are critical for generating meaningful multiomics data.
In multiomics research, comprehensive biological data from infected individuals is essential to understand the molecular mechanisms of infection, immune response, and viral latency. However, the asymptomatic presentation often results in underdiagnosis and underreporting, limiting the availability of well-characterized clinical samples. This scarcity hampers the ability to identify reliable biomarkers or molecular signatures associated with different stages of HSV infection.
Key Market Trends
Expansion of Home Testing
The expansion of home testing is an emerging trend significantly influencing the United States multiomics market. For instance, at-home over-the-counter (OTC) COVID-19 diagnostic tests can determine the presence of an active COVID-19 infection. These tests are FDA-authorized for self-administration without a prescription, either at home or in other non-clinical settings. As consumers increasingly seek convenient, accessible, and personalized healthcare solutions, the integration of multiomics technologies into home-based testing platforms is gaining momentum. This trend aligns with the broader shift toward patient-centric care and digital health innovation within the U.S. healthcare landscape.
Home testing powered by multiomics enables individuals to gain comprehensive insights into their genetic, proteomic, and metabolic profiles without the need for frequent clinical visits. Advances in sample collection methods, such as minimally invasive kits for saliva, blood, or urine, combined with robust analytical technologies, have made it feasible to perform complex multiomic analyses outside traditional laboratory settings. This accessibility enhances early disease detection, wellness monitoring, and personalized health management directly in the consumer’s home.
Key Market Players
In this report, the United States Multiomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the United States Multiomics Market.
Available Customizations:
United States Multiomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
United States Multiomics Market was valued at USD 1.03 Billion in 2024 and is expected to reach USD 1.39 Billion by 2030 with a CAGR of 5.28%. Multiomics integrates data from multiple molecular layers to offer a more holistic view of health, disease, and drug response, making it a powerful tool in precision medicine, drug discovery, and clinical diagnostics. In the U.S., this market is expanding due to strong investment in life sciences research, increasing adoption of personalized healthcare, and the availability of advanced technological platforms.
Academic institutions, biotechnology firms, and pharmaceutical companies are leveraging multiomics to uncover complex disease mechanisms, identify novel biomarkers, and develop more targeted therapies. Despite its potential, the U.S. multiomics market faces challenges, particularly in terms of data integration, standardization, and interpretation. Managing large, complex datasets across different omics platforms requires robust bioinformatics capabilities and advanced computational infrastructure. There is also a growing need for skilled professionals who can bridge the gap between molecular biology and data science.
Key Market Drivers
Growth in Healthcare Industry
The growth of the healthcare industry in the United States is a major driver of the expanding multiomics market. In 2023, U.S. healthcare expenditures increased by 7.5%, reaching a total of USD 4.9 trillion, equivalent to approximately USD 14,570 per capita. This spending represented 17.6% of the country’s Gross Domestic Product (GDP). As the sector shifts toward precision medicine and data-driven care, the demand for comprehensive, multi-layered biological analysis has surged. Multiomics, an integrated approach that combines genomics, proteomics, transcriptomics, metabolomics, and other “omics” technologies is increasingly seen as essential to understanding complex diseases and tailoring more effective treatments.
One of the most significant factors fueling this demand is the healthcare industry’s emphasis on personalized medicine. For instance, USP, headquartered in Maryland, is committed to ensuring a reliable and consistent supply of safe, high-quality medicines. Leveraging scientific expertise and capacity-building solutions, USP develops standards, practical tools, and resources that empower healthcare professionals to deliver optimal personalized care across all healthcare environments. With a growing focus on treatments that are customized to an individual’s unique biological profile, healthcare providers and researchers are turning to multiomics to uncover deeper molecular insights.
Key Market Challenges
Asymptomatic Nature of HSV Infections
The asymptomatic nature of HSV infections presents a unique challenge for the United States multiomics market, particularly in efforts to develop diagnostic tools and personalized treatment strategies. Since a significant proportion of individuals infected with Herpes Simplex Virus do not exhibit noticeable symptoms, detecting and studying the virus becomes inherently difficult. This silent transmission complicates sample collection and patient identification, which are critical for generating meaningful multiomics data.
In multiomics research, comprehensive biological data from infected individuals is essential to understand the molecular mechanisms of infection, immune response, and viral latency. However, the asymptomatic presentation often results in underdiagnosis and underreporting, limiting the availability of well-characterized clinical samples. This scarcity hampers the ability to identify reliable biomarkers or molecular signatures associated with different stages of HSV infection.
Key Market Trends
Expansion of Home Testing
The expansion of home testing is an emerging trend significantly influencing the United States multiomics market. For instance, at-home over-the-counter (OTC) COVID-19 diagnostic tests can determine the presence of an active COVID-19 infection. These tests are FDA-authorized for self-administration without a prescription, either at home or in other non-clinical settings. As consumers increasingly seek convenient, accessible, and personalized healthcare solutions, the integration of multiomics technologies into home-based testing platforms is gaining momentum. This trend aligns with the broader shift toward patient-centric care and digital health innovation within the U.S. healthcare landscape.
Home testing powered by multiomics enables individuals to gain comprehensive insights into their genetic, proteomic, and metabolic profiles without the need for frequent clinical visits. Advances in sample collection methods, such as minimally invasive kits for saliva, blood, or urine, combined with robust analytical technologies, have made it feasible to perform complex multiomic analyses outside traditional laboratory settings. This accessibility enhances early disease detection, wellness monitoring, and personalized health management directly in the consumer’s home.
Key Market Players
- Becton, Dickinson and Company
- Thermo Fisher Scientific Inc.
- Illumina, Inc
- Danaher Corporation
- PerkinElmer Inc.
- Shimadzu Corporation
- Bruker Corporation
- Agilent Technologies, Inc.
In this report, the United States Multiomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- United States Multiomics Market, By Product & Service:
- Instruments
- Consumables
- Software
- Services
- United States Multiomics Market, By Platform:
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
- United States Multiomics Market, By Region:
- Northeast
- Midwest
- South
- West
Company Profiles: Detailed analysis of the major companies present in the United States Multiomics Market.
Available Customizations:
United States Multiomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. IMPACT OF COVID-19 ON UNITED STATES MULTIOMICS MARKET
5. UNITED STATES MULTIOMICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product & Service (Instruments, Consumables, Software, Services)
5.2.2. By Platform (Genomics, Transcriptomics, Proteomics, Metabolomics, Integrated Omics Platforms)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. NORTHEAST MULTIOMICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product & Service
6.2.2. By Platform
7. MIDWEST MULTIOMICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product & Service
7.2.2. By Platform
8. SOUTH MULTIOMICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product & Service
8.2.2. By Platform
9. WEST MULTIOMICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product & Service
9.2.2. By Platform
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. DISRUPTIONS : CONFLICTS, PANDEMICS AND TRADE BARRIERS
13. UNITED STATES MULTIOMICS MARKET: SWOT ANALYSIS
14. PORTERS FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Becton, Dickinson and Company
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Thermo Fisher Scientific Inc.
15.3. Illumina, Inc
15.4. Danaher Corporation
15.5. PerkinElmer Inc.
15.6. Shimadzu Corporation
15.7. Bruker Corporation
15.8. Agilent Technologies, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. IMPACT OF COVID-19 ON UNITED STATES MULTIOMICS MARKET
5. UNITED STATES MULTIOMICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product & Service (Instruments, Consumables, Software, Services)
5.2.2. By Platform (Genomics, Transcriptomics, Proteomics, Metabolomics, Integrated Omics Platforms)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. NORTHEAST MULTIOMICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product & Service
6.2.2. By Platform
7. MIDWEST MULTIOMICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product & Service
7.2.2. By Platform
8. SOUTH MULTIOMICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product & Service
8.2.2. By Platform
9. WEST MULTIOMICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product & Service
9.2.2. By Platform
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. DISRUPTIONS : CONFLICTS, PANDEMICS AND TRADE BARRIERS
13. UNITED STATES MULTIOMICS MARKET: SWOT ANALYSIS
14. PORTERS FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Becton, Dickinson and Company
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Thermo Fisher Scientific Inc.
15.3. Illumina, Inc
15.4. Danaher Corporation
15.5. PerkinElmer Inc.
15.6. Shimadzu Corporation
15.7. Bruker Corporation
15.8. Agilent Technologies, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
